Ubiquitin enzymes are a group of enzymes that catalyze the covalent attachment of ubiquitin to other proteins. Ubiquitin is a small protein that is attached to other proteins in order to mark them for degradation by proteasomes. The ubiquitination process can be reversed by deubiquitylating enzymes, which remove the ubiquitin from the protein. There are two types of ubiquitin enzymes: E1 and E2.E1 and E2 are both involved in the formation of polyubiquitylated chains, but they differ in their mechanism for forming these chains. The first type, E1, forms polyubiquitylated chains through an ATP-dependent reaction with ATP as a substrate and UBL as an acceptor molecule; whereas the second type, E2, forms polyubiquitylated chains through an ATP-independent reaction with UBL as both substrate and acceptor molecule.
Some Of The Growth Factors Of This Market:
- Ubiquitin enzymes are used in the treatment of various diseases such as cancer, Alzheimer's disease, and Parkinson's disease.
- The ubiquitin enzymes market is driven by factors such as increasing prevalence of chronic diseases and increasing demand for personalized medicine.
- Increasing research and development activities in the field of biotechnology.
- Increasing government funding for research and development.
Industry Growth Insights published a new data on “Ubiquitin Enzymes Market”. The research report is titled “Ubiquitin Enzymes Market research by Types (E1 AND E2 ENZYMES AS THERAPEUTIC TARGETS, E3 ENZYMES AS THERAPEUTIC TARGETS, DUB ENZYMES AS THERAPEUTIC TARGETS, ASSOCIATED DRUG CLASSES), By Applications (Cancer, Biological Engineering, Others), By Players/Companies 3SBio, 5AM Ventures, Abbiotec, Abcam, AcelRx Pharmaceuticals, Aegera Therapeutics, Aeneas Ventures, Agilis Biotherapeutics, Aileron Therapeutics, Aju IB Investment, Alexion Pharmaceuticals, Almac Discovery, Amgen, Angelman Syndrome Foundation, Apeiron Biologics, Boston Biochem, Boston University Technology Development Fund, BostonBiochem, BPS Biosciences, Business Development Bank of Canada, Business Development Corporation (BDC) Capital, C4 Therapeutics, Calculus Capital, Canaan Partners, Cancer Research Technology, Captor Therapeutics, Carmot Therapeutics, Cayman Chemicals, Celgene Corporation, Cell Signaling Technology”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Ubiquitin Enzymes Market Research Report
By Type
E1 AND E2 ENZYMES AS THERAPEUTIC TARGETS, E3 ENZYMES AS THERAPEUTIC TARGETS, DUB ENZYMES AS THERAPEUTIC TARGETS, ASSOCIATED DRUG CLASSES
By Application
Cancer, Biological Engineering, Others
By Companies
3SBio, 5AM Ventures, Abbiotec, Abcam, AcelRx Pharmaceuticals, Aegera Therapeutics, Aeneas Ventures, Agilis Biotherapeutics, Aileron Therapeutics, Aju IB Investment, Alexion Pharmaceuticals, Almac Discovery, Amgen, Angelman Syndrome Foundation, Apeiron Biologics, Boston Biochem, Boston University Technology Development Fund, BostonBiochem, BPS Biosciences, Business Development Bank of Canada, Business Development Corporation (BDC) Capital, C4 Therapeutics, Calculus Capital, Canaan Partners, Cancer Research Technology, Captor Therapeutics, Carmot Therapeutics, Cayman Chemicals, Celgene Corporation, Cell Signaling Technology
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Ubiquitin Enzymes Market Report Segments:
The global Ubiquitin Enzymes market is segmented on the basis of:
Types
E1 AND E2 ENZYMES AS THERAPEUTIC TARGETS, E3 ENZYMES AS THERAPEUTIC TARGETS, DUB ENZYMES AS THERAPEUTIC TARGETS, ASSOCIATED DRUG CLASSES
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Biological Engineering, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- 3SBio
- 5AM Ventures
- Abbiotec
- Abcam
- AcelRx Pharmaceuticals
- Aegera Therapeutics
- Aeneas Ventures
- Agilis Biotherapeutics
- Aileron Therapeutics
- Aju IB Investment
- Alexion Pharmaceuticals
- Almac Discovery
- Amgen
- Angelman Syndrome Foundation
- Apeiron Biologics
- Boston Biochem
- Boston University Technology Development Fund
- BostonBiochem
- BPS Biosciences
- Business Development Bank of Canada
- Business Development Corporation (BDC) Capital
- C4 Therapeutics
- Calculus Capital
- Canaan Partners
- Cancer Research Technology
- Captor Therapeutics
- Carmot Therapeutics
- Cayman Chemicals
- Celgene Corporation
- Cell Signaling Technology
Highlights of The Ubiquitin Enzymes Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- E1 AND E2 ENZYMES AS THERAPEUTIC TARGETS
- E3 ENZYMES AS THERAPEUTIC TARGETS
- DUB ENZYMES AS THERAPEUTIC TARGETS
- ASSOCIATED DRUG CLASSES
- By Application:
- Cancer
- Biological Engineering
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ubiquitin Enzymes Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ubiquitin enzymes are proteins that catalyze the transfer of ubiquitin from one molecule to another. Ubiquitination is a process by which ubiquitin tags specific proteins for degradation, and this tagging can lead to the activation of various signaling pathways.
Some of the major players in the ubiquitin enzymes market are 3SBio, 5AM Ventures, Abbiotec, Abcam, AcelRx Pharmaceuticals, Aegera Therapeutics, Aeneas Ventures, Agilis Biotherapeutics, Aileron Therapeutics, Aju IB Investment, Alexion Pharmaceuticals, Almac Discovery, Amgen, Angelman Syndrome Foundation, Apeiron Biologics, Boston Biochem, Boston University Technology Development Fund, BostonBiochem, BPS Biosciences, Business Development Bank of Canada, Business Development Corporation (BDC) Capital, C4 Therapeutics, Calculus Capital, Canaan Partners, Cancer Research Technology, Captor Therapeutics, Carmot Therapeutics, Cayman Chemicals, Celgene Corporation, Cell Signaling Technology.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Ubiquitin Enzymes Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Ubiquitin Enzymes Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Ubiquitin Enzymes Market - Supply Chain
4.5. Global Ubiquitin Enzymes Market Forecast
4.5.1. Ubiquitin Enzymes Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Ubiquitin Enzymes Market Size (000 Units) and Y-o-Y Growth
4.5.3. Ubiquitin Enzymes Market Absolute $ Opportunity
5. Global Ubiquitin Enzymes Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Ubiquitin Enzymes Market Size and Volume Forecast by Type
5.3.1. E1 AND E2 ENZYMES AS THERAPEUTIC TARGETS
5.3.2. E3 ENZYMES AS THERAPEUTIC TARGETS
5.3.3. DUB ENZYMES AS THERAPEUTIC TARGETS
5.3.4. ASSOCIATED DRUG CLASSES
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Ubiquitin Enzymes Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Ubiquitin Enzymes Market Size and Volume Forecast by Application
6.3.1. Cancer
6.3.2. Biological Engineering
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Ubiquitin Enzymes Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Ubiquitin Enzymes Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Ubiquitin Enzymes Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Ubiquitin Enzymes Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Ubiquitin Enzymes Demand Share Forecast, 2019-2026
9. North America Ubiquitin Enzymes Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Ubiquitin Enzymes Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Ubiquitin Enzymes Market Size and Volume Forecast by Application
9.4.1. Cancer
9.4.2. Biological Engineering
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Ubiquitin Enzymes Market Size and Volume Forecast by Type
9.7.1. E1 AND E2 ENZYMES AS THERAPEUTIC TARGETS
9.7.2. E3 ENZYMES AS THERAPEUTIC TARGETS
9.7.3. DUB ENZYMES AS THERAPEUTIC TARGETS
9.7.4. ASSOCIATED DRUG CLASSES
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Ubiquitin Enzymes Demand Share Forecast, 2019-2026
10. Latin America Ubiquitin Enzymes Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Ubiquitin Enzymes Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Ubiquitin Enzymes Market Size and Volume Forecast by Application
10.4.1. Cancer
10.4.2. Biological Engineering
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Ubiquitin Enzymes Market Size and Volume Forecast by Type
10.7.1. E1 AND E2 ENZYMES AS THERAPEUTIC TARGETS
10.7.2. E3 ENZYMES AS THERAPEUTIC TARGETS
10.7.3. DUB ENZYMES AS THERAPEUTIC TARGETS
10.7.4. ASSOCIATED DRUG CLASSES
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Ubiquitin Enzymes Demand Share Forecast, 2019-2026
11. Europe Ubiquitin Enzymes Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Ubiquitin Enzymes Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Ubiquitin Enzymes Market Size and Volume Forecast by Application
11.4.1. Cancer
11.4.2. Biological Engineering
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Ubiquitin Enzymes Market Size and Volume Forecast by Type
11.7.1. E1 AND E2 ENZYMES AS THERAPEUTIC TARGETS
11.7.2. E3 ENZYMES AS THERAPEUTIC TARGETS
11.7.3. DUB ENZYMES AS THERAPEUTIC TARGETS
11.7.4. ASSOCIATED DRUG CLASSES
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y rowth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Ubiquitin Enzymes Demand Share, 2019-2026
12. Asia Pacific Ubiquitin Enzymes Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Ubiquitin Enzymes Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Ubiquitin Enzymes Market Size and Volume Forecast by Application
12.4.1. Cancer
12.4.2. Biological Engineering
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Ubiquitin Enzymes Market Size and Volume Forecast by Type
12.7.1. E1 AND E2 ENZYMES AS THERAPEUTIC TARGETS
12.7.2. E3 ENZYMES AS THERAPEUTIC TARGETS
12.7.3. DUB ENZYMES AS THERAPEUTIC TARGETS
12.7.4. ASSOCIATED DRUG CLASSES
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Ubiquitin Enzymes Demand Share, 2019-2026
13. Middle East & Africa Ubiquitin Enzymes Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Ubiquitin Enzymes Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Ubiquitin Enzymes Market Size and Volume Forecast by Application
13.4.1. Cancer
13.4.2. Biological Engineering
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Ubiquitin Enzymes Market Size and Volume Forecast by Type
13.7.1. E1 AND E2 ENZYMES AS THERAPEUTIC TARGETS
13.7.2. E3 ENZYMES AS THERAPEUTIC TARGETS
13.7.3. DUB ENZYMES AS THERAPEUTIC TARGETS
13.7.4. ASSOCIATED DRUG CLASSES
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Ubiquitin Enzymes Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Ubiquitin Enzymes Market: Market Share Analysis
14.2. Ubiquitin Enzymes Distributors and Customers
14.3. Ubiquitin Enzymes Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. 3SBio
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. 5AM Ventures
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Abbiotec
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Abcam
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. AcelRx Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Aegera Therapeutics
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Aeneas Ventures
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Agilis Biotherapeutics
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Aileron Therapeutics
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Aju IB Investment
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Alexion Pharmaceuticals
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Almac Discovery
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Amgen
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Angelman Syndrome Foundation
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Apeiron Biologics
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Boston Biochem
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Boston University Technology Development Fund
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. BostonBiochem
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. BPS Biosciences
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Business Development Bank of Canada
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
